Demodex folliculorum in patients with rheumatoid arthritis

• Autorzy: Ciftci I H , Dundar U. , Cetinkaya Z. , Kulac M. , Kiyildi N. , Turel A. , Evcik D. , Kavuncu V.
• Języki publikacji: EN

Abstrakty

EN

The objective of this study was to investigate the incidence and density of Demodex folliculorum in the patients with rheumatoid arthritis (RA). Forty-one patients with RA and twenty-seven age and sex matched healthy controls were enrolled in this study. Disease Activity Score (DAS 28) was used for the assessment of disease activity. Out of 41 patients, 33 were females and 8 males. The mean disease duration was 10.9 ± 8.2 years. The mean DAS 28 was 3.8 ± 1.2. No statistically significant differences in the incidence and density of Demodex mites were found between patients with RA and controls. Although immunosuppression is thought to be a risk factor for the D. folliculorum infestation no such correlations could be found in the 41 immunosuppressed patients with RA, therefore, further studies with larger groups are needed.

Słowa kluczowe

EN

human disease; patient; disease activity; mite; immunosuppression; rheumatoid arthritis; Demodex folliculorum

• Wydawca: -
• Czasopismo: Acta Parasitologica
• Rocznik: 2007
• Tom: 52
• Numer: 1
• Opis fizyczny: p.70-73,ref.

Twórcy

autor

Ciftci I H

• Kocatepe University, Afyon, Turkey

autor

Dundar U.

autor

Cetinkaya Z.

autor

Kulac M.

autor

Kiyildi N.

autor

Turel A.

autor

Evcik D.

autor

Kavuncu V.

Bibliografia

• Akdeniz S., Bahceci M., Tuzcu A.K., Harman M., Alp S., Bahceci S. 2002. Is Demodex folliculorum larger in diabetic patients? Journal of the European Academy of Dermatology and Venereology, 16, 539–541.
• Akilov O.E., Mumcuoglu K.Y. 2003. Association between human demodicosis and HLA class I. Clinical and Experimental Dermatology, 28, 70–73.
• Aydıngoz I.E., Dervent B., Guney O. 2000. Demodex folliculorum in pregnancy. International Journal of Dermatology, 39, 743–745.
• Baima B., Sticherling M. 2002. Demodicidosis revisited. Acta Dermato-Venereologica, 82, 3–6.
• Castanet J., Monpoux F., Mariani R., Ortonne J.P., Lacour J.P. 1997. Demodicidosis in an immunodeficient child. Pediatric Dermatology, 14, 219–220.
• Damian D., Rogers M. 2003. Demodex infestation in a child with leukaemia: treatment with ivermectin and permethrin. International Journal of Dermatology, 42, 724–726.
• Davis L.S., Sackler M., Brezinschek R.I., Lightfoot E., Bailey J.L., Oppenheimer-Marks N., Lipsky P.E. 2002. Inflammation, immune reactivity and angiogenesis in a severe combined immunodeficiency model of rheumatoid arthritis. American Journal of Pathology, 160, 357–367.
• Firestein G.S. 2001. Etiology and pathogenesis of rheumatoid arthritis. In: Kelley’s textbook of rheumatology (Eds. S. Ruddy, E.D. Jr. Harris and C.B. Sledge). W.B. Saunders, Philadelphia, 921–966.
• Forton F., Song M. 1998. Limitation of standardized skin surface biopsy in measurement of the density of Demodex folliculorum. A case report. British Journal of Dermatology, 139, 697–700.
• Goldenber M.M. 1999. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis. Clinical Therapeutics, 21, 1837–1852.
• Goronzy J.J., Weyand C.M. 2003. Aging, autoimmunity and arthritis: T-cell senescence and contraction of T-cell repertoire diversity — catalysts of autoimmunity and chronic inflammation. Arthritis Research and Therapy, 5, 225–234.
• Herman S., Zurgil N., Langevitz P., Ehrenfeld M., Deutsch M. 2004. The immunosuppressive effect of methotrexate in active rheumatoid arthritis patients vs. its stimulatory effect in nonactive patients, as indicated by cytometric measurements of CD4+ T cell subpopulations. Immunological Investigations, 33, 351–362.
• Hernandez-Cruz B., Cardiel M.H., Villa A.R., Alcocer-Varele J. 1998. Development, recurrence, and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study. Journal of Rheumatology, 25, 1900–1907.
• Jansen T., Kastner U., Kreuter A., Altmeyer P. 2001. Rosacea-like demodicidosis associated with acquired immunodeficiency syndrome. British Journal of Dermatology, 144, 139–142.
• Karincaoglu Y., Bayram N., Aycan O., Esrefoglu M. 2004. The clinical importance of Demodex folliculorum presenting with nonspecific facial signs and symptoms. Journal of Dermatology, 31, 618–626.
• Lee C.S., Chang C.K. 2003. Brain abscess in rheumatoid arthritis. Annals of the Rheumatic Diseases, 62, 689–690.
• Patrizi A., Neri I., Chieregato C., Misciali M. 1997. Demodicidosis in immunocompetent young children: report of eight cases. Dermatology, 195, 239–242.
• Sakuntabhai A., Timpatanapong P. 1991. Topical steroid induced chronic demodicidosis. Journal of the Medical Association of Thailand, 74, 116–119.
• Schnabel A., Herlyn K., Burchardi C., Reinhold-Keller E., Gross W.L. 1996. Long-term tolerability of methotrexate at doses exceeding 15 mg per week in rheumatoid arthritis. Rheumatology International, 15, 195–200.
• Seyhan M.E., Karincaoglu Y., Bayram N., Aycan O., Kuku I. 2004. Density of Demodex folliculorum in haematological malignancies. Journal of International Medical Research, 3, 411–415.
• Stastny P., Ball E.J., Khan M.A., Olsen N.J., Pincus T., Gao X. 1998. HLA-DR4 and other genetic markers in rheumatoid arthritis. British Journal of Rheumatology, 27,Suppl. II, 132–138.
• Ulusoy H., Bilgici A., Kuru O., Celenk C. 2005. Pulmonary abscess due to leflunomide use in rheumatoid arthritis: a case report. Rheumatology International, 25, 139–142.
• Van der Veen M.J., Van der Heide A., Kruize A.A., Bijlsma J.W. 1994. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Annals of the Rheumatic Diseases, 53, 224–228.
• Wahl C., Liptay S., Adler G., Schmid R.M. 1998. Sulfasalazine: a potent and a specific inhibitor of nuclear factor kappa B. Journal of Clinical Investigation, 101, 1163–1174.